{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:03:34Z","timestamp":1777511014791,"version":"3.51.4"},"reference-count":92,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pharmacokinetic boosting of antiretroviral (ARV) therapies with either ritonavir or cobicistat is used to achieve target drug exposure, lower pill burden, and provide simplified dosing schedules. Several ARVs require boosting, including the integrase inhibitor elvitegravir as well as protease inhibitors such as darunavir, atazanavir, and lopinavir. The use of boosted regimens in pregnant women living with HIV has been studied for a variety of ARVs; however, a recent recommendation by the US Food and Drug Administration advised against cobicistat\u2010boosted regimens in pregnancy due to substantially lower drug exposures observed in clinical pharmacokinetic studies. The objectives of this article are to review pharmacokinetic enhancement of ARVs with ritonavir and cobicistat during pregnancy and postpartum, describe clinical implications, and provide recommendations for future research.<\/jats:p>","DOI":"10.1002\/jcph.1714","type":"journal-article","created":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T07:51:53Z","timestamp":1597477913000},"page":"1537-1550","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacokinetic Enhancement of HIV Antiretroviral Therapy During Pregnancy"],"prefix":"10.1002","volume":"60","author":[{"given":"Engie","family":"Salama","sequence":"first","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences University of California, San Diego  La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0070-9840","authenticated-orcid":false,"given":"Ahizechukwu C.","family":"Eke","sequence":"additional","affiliation":[{"name":"Division of Maternal Fetal Medicine &amp; Clinical Pharmacology, Department of Gynecology &amp; Obstetrics Johns Hopkins University School of Medicine  Baltimore Maryland USA"},{"name":"Doctoral Training Program (PhD), Graduate Training Program in Clinical Investigation (GTPCI) Johns Hopkins University School of Public Health  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brookie M.","family":"Best","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences University of California, San Diego  La Jolla California USA"},{"name":"Department of Pediatrics University of California San Diego \u2013 Rady Children's Hospital San Diego  San Diego California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Mirochnick","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics Boston University School of Medicine  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremiah D.","family":"Momper","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences University of California, San Diego  La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States.https:\/\/files.aidsinfo.nih.gov\/contentfiles\/lvguidelines\/PerinatalGL.pdf. Accessed July 14 2020."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443150-00002"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semperi.2015.08.003"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0167-9"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199704000-00001"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh029"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1237"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002163"},{"key":"e_1_2_9_10_1","unstructured":"MomperJD StekA WangJ et\u00a0al. Pharmacokinetics of atazanavir boosted with cobicistat during pregnancy and postpartum. Presented at: 20th International Workshop on Clinical Pharmacology of HIV Hepatitis and Other Antiviral Drugs; May 16 2019; Noordwijk the Netherlands."},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2011.572905"},{"issue":"7","key":"e_1_2_9_12_1","first-page":"938","article-title":"Marked hyperlipidaemia on ritonavir therapy","volume":"11","author":"Sullivan AK","year":"1997","journal-title":"AIDS"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200202011-00003"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K615"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000125"},{"key":"e_1_2_9_16_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf. Accessed July 14 2020."},{"key":"e_1_2_9_17_1","first-page":"962574","article-title":"Efficacy of once daily darunavir\/ritonavir in PI\u2010naive, NNRTI\u2010experienced patients in the ODIN Trial","volume":"2015","author":"Geretti AM","year":"2015","journal-title":"AIDS Res Treat"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2012.01060.x"},{"key":"e_1_2_9_19_1","unstructured":"SekarV Vanden AbeeleC Van BaelenB et\u00a0al. Pharmacokinetic\u2010pharmacodynamic analyses of once\u2010daily darunavir\u2010ritonavir in the ARTEMIS study. Poster session presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3\u20106 2008; Boston MA."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12366"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku400"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12047"},{"issue":"1","key":"e_1_2_9_23_1","first-page":"16","article-title":"Pharmacokinetics and safety of darunavir\/ritonavir in HIV\u2010infected pregnant women","volume":"19","author":"Khoo S","year":"2017","journal-title":"AIDS Rev"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002261"},{"key":"e_1_2_9_25_1","unstructured":"2019 Janssen Pharmaceuticals Titusville NJ Prezista (darunavir) [package insert]"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31820fd093"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx274"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32825a69d1"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318289b4d2"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12164"},{"issue":"5","key":"e_1_2_9_31_1","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/135965350400900520","article-title":"The plasma and intracellular steady\u2010state pharmacokinetics of lopinavir\/ritonavir in HIV\u20101\u2010infected patients","volume":"9","author":"Crommentuyn KM","year":"2004","journal-title":"Antivir Ther"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr490"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02455.x"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05186-11"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct0804-254"},{"issue":"1","key":"e_1_2_9_36_1","first-page":"38","article-title":"Safety and efficacy of lopinavir\/ritonavir during pregnancy: a systematic review","volume":"15","author":"Pasley MV","year":"2013","journal-title":"AIDS Rev"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181d6c9ed"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318186edd0"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2010.00865.x"},{"key":"e_1_2_9_40_1","unstructured":"2019 AbbVie Inc North Chicago IL Kaletra (lopinavir\/ritonavir) [package insert]"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku367"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01197-15"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2009.00767.x"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31827fd47e"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2013.0159"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2012.07.010"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318236376d"},{"issue":"8","key":"e_1_2_9_48_1","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/135965350801300820","article-title":"Pharmacokinetics, safety and efficacy of saquinavir\/ ritonavir 1,000\/100 mg twice daily as HIV type\u20101 therapy and transmission prophylaxis in pregnancy","volume":"13","author":"Hentig N","year":"2008","journal-title":"Antivir Ther"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02260-19"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12078"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01301-07"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.228"},{"key":"e_1_2_9_53_1","unstructured":"2019 Gilead Foster City CA Tybost (cobicistat) [package insert]"},{"key":"e_1_2_9_54_1","unstructured":"2019 AbbVie Inc North Chicago IL Norvir (ritonavir) [package insert]"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml1000257"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2019.1628947"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01089-12"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182645648"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181eb376b"},{"key":"e_1_2_9_60_1","unstructured":"RamanathanS WarrenD WeiL KearneyBP. Pharmacokinetic boosting of atazanavir with the pharmacoenhancer GS\u20109350 versus ritonavir (abstract 614). Poster session presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12\u201015 2009; San Francisco CA."},{"key":"e_1_2_9_61_1","unstructured":"MathiasA LiuH WarrenD SekarV KearneyBP. Relative bioavailability and pharmacokinetics of darunavir when boosted with pharmacoenhancer GS\u20109350 versus ritonavir (abstract 28). Poster session presented at: 11th International Workshop on Clinical Pharmacology of HIV Therapy; April 7\u20109 2010; Sorrento Italy."},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001992"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13310"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019830788"},{"key":"e_1_2_9_65_1","unstructured":"MomperJD BestBM WangJ et\u00a0al. Pharmacokinetics of darunavir boosted with cobicistat during pregnancy and postpartum. Poster session presented at: 22nd International AIDS Conference; July 23\u201027 2018; Amsterdam the Netherlands."},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12721"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1397"},{"key":"e_1_2_9_68_1","unstructured":"MomperJD BestBM WangJ et\u00a0al. Tenofovir alafenamide pharmacokinetics with and without cobicistat in pregnancy. Podium presentation at: 22nd International AIDS Conference; July 23\u201027 2018; Amsterdam the Netherlands."},{"key":"e_1_2_9_69_1","unstructured":"BrooksKM PinillaM ShapiroD et\u00a0al. Pharmacokinetics of tenofovir alafenamide 25 mg with PK boosters during pregnancy and postpartum. Podium presentation at: 20th International Workshop on Clinical Pharmacology of HIV Hepatitis & Other Antiviral Drugs; May 14\u201016 2019; Noordwijk the Netherlands."},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2020.1738384"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu709"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00831"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1106-303"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834982af"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1815325"},{"key":"e_1_2_9_76_1","unstructured":"Task Force on Research Specific to Pregnant Women and Lactating Women. Report to Secretary Health and Human Services and Congress.2018;https:\/\/www.nichd.nih.gov\/sites\/default\/files\/2018-09\/PRGLAC_Report.pdf. Accessed July 7 2020."},{"key":"e_1_2_9_77_1","unstructured":"US Food and Drug Administration. Guidance for Industry.Pregnant women: scientific and ethical considerations for inclusion in clinical trials.2018;https:\/\/www.fda.gov\/media\/112195\/download. Accessed July 5 2020."},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-2402-9"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30296-0"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19824"},{"key":"e_1_2_9_81_1","unstructured":"S GulnikM AfoninaE. Preclinical and early clinical evaluation of SPI\u2010452 a new pharmacokinetic enhancer [abstract]. Poster session presented at: 16th Conference on Retroviruses and Opportunistic Infections (CROI); February 8\u201011 2009; Montreal Canada."},{"key":"e_1_2_9_82_1","unstructured":"Pfizer. Glaxo SmithKline (GSK) and Pfizer's ARV pipeline.https:\/\/www.nature.com\/articles\/nrd2917\/tables\/1. Accessed March 22 2020."},{"key":"e_1_2_9_83_1","unstructured":"Tibotec. PEPI\u2010TiDP23\u2010C103: First\u2010in\u2010human study to examine the safety tolerability and plasma pharmacokinetics of increasing single and repeated oral doses of TMC558445 and of a combined single day dosing of oral TMC558445 and oral TMC310911 and also oral darunavir.https:\/\/aidsinfo.nih.gov\/clinical-trials\/details\/NCT00838760. Accessed March 22 2020."},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.3390\/scipharm86040043"},{"key":"e_1_2_9_85_1","unstructured":"CollinsS. HIV pipeline 2020: new drugs in development \u2013 March2020.http:\/\/i-base.info\/htb\/wp-content\/uploads\/2020\/03\/i-Base-HIV-pipeline-March-2020.pdf. Accessed March 22 2020."},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000668"},{"key":"e_1_2_9_87_1","unstructured":"2019 Bristol\u2010Myers Squibb Company Princeton NJ Reyataz (atazanavir) [package insert]"},{"key":"e_1_2_9_88_1","unstructured":"2017 GlaxoSmithKline Research Triangle Park NC Lexiva (fosamprenavir) [package insert]"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000976"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000247114.43714.90"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp123"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328347f7e9"},{"key":"e_1_2_9_93_1","unstructured":"ColbersA SchalkwijkS KonopnickiD RockstrohJ BurgerD.Elvitegravir pharmacokinetics during pregnancy and postpartum. Presented at: 19th International Workshop on Clinical Pharmacology of Antiviral Therapy; May 22\u201324 2018; Baltimore MD. Abstract 17.http:\/\/www.natap.org\/2018\/Pharm\/Pharm_11.htm. Accessed August 4 2020."}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.1714","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1714","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.1714","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T11:04:20Z","timestamp":1693566260000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.1714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":92,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1002\/jcph.1714"],"URL":"https:\/\/doi.org\/10.1002\/jcph.1714","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]},"assertion":[{"value":"2020-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}